Osteoarthritis year 2011 in review: Biochemical markers of osteoarthritis: An overview of research and initiatives

Osteoarthritis and Cartilage

Volumn 20, Issue 3, 2012, Pages 215-217

  Henrotin, Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Biomarkers; Cartilage; Osteoarthritis; Proteome

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 MICROGLOBULIN; ALPHA2 GLYCOPROTEIN; AMYLOID P COMPONENT; APOLIPOPROTEIN; APOPTOSIS INDUCING FACTOR; BETA ACTIN; BETA THROMBOGLOBULIN; BIOCHEMICAL MARKER; COLLAGEN TYPE 2; COMPLEMENT; COMPLEMENT COMPONENT C3B; FIBRINOGEN; FIBULIN; IMMUNOGLOBULIN; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; PROTEIN; PROTEOGLYCAN; PROTEOME; SCLEROPROTEIN; SERINE PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA; VITRONECTIN;

AMINO ACID SEQUENCE; ARTICULAR CARTILAGE; BODY FLUID; CARTILAGE CELL; CELL DIFFERENTIATION; CELL VACUOLE; DISEASE SEVERITY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; MASS SPECTROMETRY; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN URINE LEVEL; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SERUM; URINE;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; HUMANS; OSTEOARTHRITIS; PROTEOME;

EID: 84857138737     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2012.01.008     Document Type: Review

References (18)

1. Kraus V., Burnette B., Coindreau J., Cottrell S., Eyre D., Gendreau M., et al. OARSI/FDA Osteoarthritis Biomarkers Working group. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cart 2011, 19:515-542.
2. De Seny D., Sharif M., Fillet M., Cobraiville G., Meuwis M.-A., marée R., et al. Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis. Ann Rheum Dis 2011, 70:1144-1152.
3. Henrotin Y., Gharbi M., Deberg M., Dubuc J.E., De Pauw E. Fibulin-3 fragments (Fib3-1 and Fib3-2) are potential new biomarkers for the diagnosis of osteoarthritis. Osteoarthritis Cart 2011, 19(Suppl 1):S79.
4. Albig A.R., Neil J.R., Schiemann W.P. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006, 66:2621-2629.
5. Ehlermann J., Weber S., Pfisterer P., Schorle H. Cloning, expression and characterization of the murine Efemp1, a gene mutated in Doyne-Honeycomb retinal dystrophy. Gene Expr Patterns 2003, 3:441-447.
6. Klenotic P.A., Munier F.L., Marmorstein L.Y., Anand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 2004, 279:30469-30473.
7. Sahebjam S., Khokha R., Mort J.S. Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum 2007, 56:905-909.
8. Kevorkian L., Young D.A., Darrah C., Donell S.T., Shepstone L., Porter S., et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004, 50:131-141.
9. Wakabayashi T., Matsumine A., Nakazora S., Hasegawa M., Iino T., Ota H., et al. Fibulin-3 negatively regulates chondrocyte differentiation. Biochem Biophys Res Commun 2010, 391:1116-1121.
10. Rosenthal A.K., Gohr C.M., Nimomiya J., Wakim T. Proteomic analysis of articular cartilage vesicles from normal and osteoarthritis cartilage. Arthritis Rheum 2011, 63:401-411.
11. Bay-Jensen A.C., Liu Q.J., Byrjalsen I., Li Y., Wang J., Pedersen C., Leeming D.J., et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM - Increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011, 44:423-429.
12. Catterall J., Hsueh M.-F., Stabler T.V., Renner J.M., Jordan J.M., Kraus V.B. A unique deamidated cartilage oligomeric matrix protein (COMP) biomarker preferentially identifies hip osteoarthritis. Osteoarthritis Cart 2011, 19(Suppl 1). S72(142).
13. Richette P., Poitou C., Garnero P., Vicaut E., Bouillot J.L., Lacorte J.M., et al. Benefit of massive loss on symptoms, systematic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis 2011, 70:139-144.
14. Denoble A., Huffman K., Stabler T., Kelley S.J., Hershfield M.S., Mcdaniel G., et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci USA 2011, 108:2088-2093.
15. Golightly Y.M., Marshall S.W., Kraus V.B., Renner J.B., Villaveces A., Casteel C., et al. Biomarkers of incident radiographic knee osteoarthritis. Arthritis Rheum 2011, 63:2276-2283.
16. Eckstein F., Hellio Le Graverand M.P., Charles H.C., Hunter D.J., Kraus V.B., Sunyer T., et al. Clinical, radiographic, molecular and MRI-based predictors of cartilage loss in knee osteoarthritis. Ann Rheum Dis 2011, 70:1223-1230.
17. Berry P.A., Maclewicz R.A., Wluka A.E., Downey-Jones M.D., Forbes A., Hellawell C.J., et al. Relationship of serum markers of cartilage metabolism to imaging and clinical outcome measures of knee joint structure. Ann Rheum Dis 2010, 69:1816-1822.
18. Pelletier J.P., Raynauld J.P., Caron J., Mineau F., Abram F., Dorais M., et al. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis 2010, 69:2095-2101.